{
  "source": "PA-Med-Nec-Verkazia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2274-4\nProgram Prior Authorization – Medical Necessity\nMedication Verkazia® (cyclosporine 0.1% ophthalmic emulsion)\nP&T Approval Date 5/2022, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nVerkazia (cyclosporine 0.1%) ophthalmic emulsion is indicated for the treatment of vernal\nkeratoconjunctivitis in children and adults.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Verkazia will be approved based on both the following criteria:\na. Diagnosis of moderate to severe vernal keratoconjunctivitis\n-AND-\nb. History of failure, contraindication, or intolerance to two of the following categories:\n1. ophthalmic antihistamines (e.g., azelastine, olopatadine)\n2. ophthalmic mast cell stabilizers (e.g., cromolyn sodium)\n3. ophthalmic corticosteroids (e.g., dexamethasone, prednisolone, fluorometholone)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Verkazia will be approved based on the following criterion:\na. Documentation of positive clinical response\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n© 2025 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Programs:\n• Supply limits may be in place\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Verkazia [package insert]. Emeryville, CA: Santen Inc.; June 2022.\n2. Leonardi A, Doan S, Amrane M, et al. A Randomized, Controlled Trial of Cyclosporine A\nCationic Emulsion in Pediatric Vernal Keratoconjunctivitis. Ophthalmology 2019;126(5):671-\n681.\n3. Conjunctivitis P",
    "eonardi A, Doan S, Amrane M, et al. A Randomized, Controlled Trial of Cyclosporine A\nCationic Emulsion in Pediatric Vernal Keratoconjunctivitis. Ophthalmology 2019;126(5):671-\n681.\n3. Conjunctivitis Preferred Practice Pattern. American Academy of Ophthalmology. 2023.\nProgram Prior Authorization – Medical Necessity - Verkazia\nChange Control\n5/2022 New program.\n5/2023 Annual review. Updated references.\n5/2024 Annual review. No changes.\n5/2025 Annual review. No changes.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}